BBS-Bioactive Bone Substitutes Plc’s Board of Directors has decided to launch an initial public offering beginning on 5.2.2018 (the ”Offering”), and the Company plans to apply to have its shares listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy and the Nasdaq First North Sweden marketplace maintained by Nasdaq OMX Stockholm AB.
The Company has decided to initially issue a maximum of 1,400,000 new shares in the Offering (the “Offer Share”). The subscription price in the Offering is EUR 5.50 per offered share (the ”Subscription Price”). If all of the Offer Shares are subscribed for and the subscriptions approved, the Offer Shares represent approximately 31.4 per cent of the Company’s shares and votes before the Offering and a maximum of approximately 23.9 per cent after the Offering, provided that all of the Offer Shares initially offered in the Offering are subscribed for in full. The Company’s objective is raise approximately EUR 7.7 million from the Offering prior to fees and expenses related to the Offering, assuming that all of the new shares are subscribed for.
Important dates (times are Finnish time)
• Launch 31st January 2018 at 11:00 a.m.
• The listing prospectus in English will be available (estimate) on 5th February 2018
• The subscription period for the Offering commences on 5th February 2018 at 09:30 a.m.
• The subscription period may be discontinued at the earliest (estimate) on 16th February 2018 at 4:30 p.m.
• The subscription period ends (estimate) on 18th February 2018 at 12:00 p.m.
• The final result of the Offering will be announced no later than (estimate) 20th February 2018
• The Offer Shares are recorded in the Trade Register and securities accounts (estimate) 26th February 2018
• Trading in the Shares commences on First North Finland and First North Sweden (estimate) on 28th February 2018
BBS-Bioactive Bone Substitutes Plc (”BBS”) is a Finnish health technology company that has developed a new generation innovative medical device product for the treatment of bone defects in orthopaedic and traumatological surgery. The Company has no turnover.
BBS-Bioactive Bone Substitutes Plc was established in 2003. A seven-year product development project at the University of Oulu preceded the establishment of the Company. The Company’s domicile is Oulu, and it has 12 employees. The Company also has a scientific advisory board consisting of medical experts. The Company has an authorised production facility for bone protein extract and is in the process of obtaining ISO 13485 certification for the ARTEBONE® implant production line.
The Company’s first product ARTEBONE® is an injectable paste in a ready-to-use syringe, injected into the bone’s problem spot or fracture area. It is designed to promote the natural healing of the bone by utilising growth factors extracted from reindeer bone and tricalcium phosphate (TCP) ceramics that act as a base for bone formation. All of the preclinical testing and clinical tests have been done, and the Company has launched the application process for the CE mark. The CE mark is a prerequisite for the commercialisation of ARTEBONE® in the EU area.
ARTEBONE®’s benefit is that it reduces expensive operating room time compared to the use of the patient’s own bone and speeds up the patient’s recovery time, as well as reducing treatment costs.
The objective of the Offering is primarily to enable the Company to raise funds to complete ARTEBONE®’s ongoing application processes for the CE mark and FDA approval, begin commercial production and the commercialisation of the product. Funds are also needed to continue product development, develop and maintain the patent portfolio, ensure sufficient self-financing for growth investments in accordance with the Company’s strategy and hire additional staff for sales and marketing. The use of the funds is described in more detail in the Listing Prospectus.
The Shares of Initial Public Offering are offered to be subscribed at EUR 5,50 per share. The Initial Public Offering Shares in Sweden, delivered by Euroclear Sweden, shall be paid in Swedish krona with EUR/SEK forward rate as described in Prospectus. The minimum subscription in Retail Offering is 200 Shares of Initial Public Offering and the maximum subscription In Retail Offering is 20 000 shares. The investors who subscribe 20 001 shares in minimum are eligible to participate in the Institutional Offering in Finland.
The Subscription period of the Initial public offering Shares (”Subscription period”) begins on 5.2.2018 at 09:30 Finnish time (at 08:30 Swedish time) and it ends in Finland on 18.2.2018 at 24:00 Finnish time and in Sweden at 24:00 Swedish time unless the Company decides to shorten or extend the Subscription period during the Subscription period.
The subscription place of the Initial Public Offering Shares (”Subscription Place”) in the Finnish Retail Offering is the Finnish branch of Nordnet Bank AB, www.nordnet.fi/bone . In the online service it is possible to subscribe with online bank user identifiers of Nordnet as well with identifiers of Aktia, Danske Bank, Handelsbanken, Nordea, Oma Säästöpankki, OP Bank, POP Bank, S-Bank, Säästöpankki and Ålandsbanken. When separately agreed the subscriber in the Retail Offering may make the subscription also at the customer service of the Finnish branch of Nordnet Bank AB, address Yliopistonkatu 5, 00100 Helsinki on business day between 09:30 and 16:30.
The subscription place in the Finnish Institutional Offering is the Finnish branch of Nordnet Bank AB, address Yliopistonkatu 5, 00100 Helsinki, tel. +358 9 68178444 and the head office of the Company, the address of which is Kiviharjunlenkki 6, 90220 Oulu; firstname.lastname@example.org.
The Subscription place in the Swedish Retail and Institutional offerings is Nordnet Bank AB, www.nordnet.se/bbs . The subscriptions are made in the subscription system of Nordnet Bank AB.
Investors are advised to carefully review the financial figures, risks and prospectus presented in the Listing Prospectus in their entirety.
• The listing prospectus in English
• The terms of the IPO
• Articles of Association
• BBS Plc’s Balance book (Annual report, Financial statement and Audit report 1.1. – 31.12.2017)
• BBS Plc’s Balance book (Annual report, Financial statement and Audit report (in Finnish) 1.1. – 31.12.2016)
• BBS Plc’s Balance book (Annual report, Financial statement and Audit report (in Finnish) 1.1. – 31.12.2015)
• Marketing Brochure (in Finnish)
• Investor presentation (in Finnish)
Live: BBS-Bioactive Bone Substitutes company presentation 6.2.2018 in Helsinki Nordnet: